Drug · CHEMBL186
CEFEPIME
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CEFEPIME. Drugs and targets, record CHEMBL186. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL186
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 4 of its 15 diseases, from ATC, EMA Human Drugs and TTD
- Open Targets
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases15
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 15Source Open Targets
See all 15 diseasesTrials57
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 1 more that Open Targets linked to it is not shown, since the release's checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT05094154 | Effect of Antibiotic Choice On ReNal Outcomes (ACORN) | Phase 4 | 2,634 | 2023-12-22 | cefepime | Its name | ClinicalTrials.gov |
| NCT03840148 | Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections | Phase 3 | 661 | 2024-05-29 | cefepime/vnrx-5133 | Open Targets' reading, confirmed by the trial's result groups and NLM's indexing of its papers | ClinicalTrials.gov |
| NCT05887908 | Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis | Phase 3 | 614 | 2025-11-25 | cefepime | Its name | ClinicalTrials.gov |
| NCT05977868 | Comparing Oral Versus Parenteral Antimicrobial Therapy | Phase 4 | 94 | 2025-08-26 | cefepime | Its name | ClinicalTrials.gov |
| NCT01110408 | A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections | Phase 3 | 41 | 2014-07-02 | cefepime | Its name | ClinicalTrials.gov |
| NCT05102162 | BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia | Phase 4 | 35 | 2023-12-12 | cefepime | Its name | ClinicalTrials.gov |
| NCT02302092 | An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections | Phase 3 | 13 | 2017-10-27 | cefepime | Its name | ClinicalTrials.gov |
| NCT01110421 | A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia | Phase 3 | 7 | 2014-07-02 | cefepime | Its name | ClinicalTrials.gov |
| NCT05079620 | Early Antibiotics After Aspiration in ICU Patients | Phase 4 | 5 | 2025-12-30 | cefepime | Its name | ClinicalTrials.gov |
| NCT00529282 | A Study of Ceftobiprole in Patients With Fever and Neutropenia. | Phase 3 | 2 | 2010-03-29 | cefepime | Its name | ClinicalTrials.gov |
1 to 10 of 57
See all 57 trialsComparisons in its trials39
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: Major Adverse Kidney Events Within 14 Days (MAKE14) | 124 of 1,214 | 114 of 1,297 | 2,511 | NCT05094154 | Trial comparisons |
| Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: deaths from any cause | 104 of 1,214 | 106 of 1,297 | 2,511 | NCT05094154 | Trial comparisons |
| Anti-pseudomonal Cephalosporin vs Anti-pseudomonal Penicillin: serious adverse events | 0 of 1,214 | 0 of 1,297 | 2,511 | NCT05094154 | Trial comparisons |
| Experimental vs Control: deaths from any cause | 1 of 64 | 0 of 30 | 94 | NCT05977868 | Trial comparisons |
| Experimental vs Control: serious adverse events | 18 of 64 | 7 of 30 | 94 | NCT05977868 | Trial comparisons |
| Group 1 (Experimental) vs Group 2 (Control): Adverse Events Related to Antimicrobial Therapy | 4 of 62 | 4 of 28 | 90 | NCT05977868 | Trial comparisons |
| Group 1 (Experimental) vs Group 2 (Control): Overall Readmission | 17 of 62 | 7 of 28 | 90 | NCT05977868 | Trial comparisons |
| Group 1 (Experimental) vs Group 2 (Control): Cure/Control at 3 Months | 61 of 62 | 28 of 28 | 90 | NCT05977868 | Trial comparisons |
| Group 1 (Experimental) vs Group 2 (Control): Adverse Events Related to Vascular Access | 0 of 62 | 7 of 28 | 90 | NCT05977868 | Trial comparisons |
| Group 1 (Experimental) vs Group 2 (Control): Number of Participants Reporting 'Satisfied' or 'Very Satisfied' on Patient Satisfaction Survey | 60 of 61 | 27 of 28 | 89 | NCT05977868 | Trial comparisons |
1 to 10 of 39
See all 39 comparisons in its trialsPapers from its trials30
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL186
GET https://conductscience.org/api/drugs/v1/CHEMBL186/trials?page=2